B&D Nutritional Ingredients Announces New Customer Product Launch—A Nutritional Supplement System Supporting GLP-1 Medication Users
04 déc. 2024 09h00 HE
|
B&D Nutritional Ingredients
NUTRILINQ™ is a physician-formulated nutritional system touted as the first science-backed nutritional support system for GLP-1 medication users.
Kailera Therapeutics Appoints Scott M. Akamine as Chief Legal Officer
12 nov. 2024 08h00 HE
|
Kailera Therapeutics, Inc.
Today, Kailera Therapeutics announced the appointment of Scott Akamine as Chief Legal Officer.
Tiziana Life Sciences to Participate in BIO-Europe 2024 to Discuss Recent Clinical Advancements, Including Positive GLP-1 Combination Study Data
01 nov. 2024 13h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3 Combination Study
30 oct. 2024 08h30 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®
28 oct. 2024 07h00 HE
|
Evoke Pharma, Inc.
Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing significant statistical improvement for GIMOTI over Oral Metoclopramide in All...
New Study Finds Trimsulin Achieves 243% Greater Weight Loss than Semaglutide without Serious Side Effects
24 oct. 2024 08h30 HE
|
FirstFitness Nutrition
New Study Finds Trimsulin Achieves 243% Greater Weight Loss than Semaglutide without Side Effects Offering a Natural GLP-1 Alternatative for Weight Loss.
Noom Unveils Two New Enterprise Products to Help Employers Offer, Manage, and Effectively Control GLP-1 Expenses
21 oct. 2024 08h02 HE
|
Noom Inc
Noom is tackling the problem of GLP-1 availability, accessibility and inflated costs by launching two distinct enterprise solutions.
Noom Introduces Innovative In-App Body Scan Technology to Monitor Muscle-Mass Retention During GLP-1 Treatment
17 oct. 2024 08h02 HE
|
Noom Inc
Noom announced that it is expanding its in-app capabilities to include a revolutionary body scan feature.
Sesame, America’s Low-Cost Leader in Healthcare, Is First Major Direct-to-Consumer Weight Loss Company to Offer Compounded Semaglutide to All 50 United States
16 oct. 2024 08h05 HE
|
Sesame
NEW YORK CITY, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sesame, the company that offers Americans quality, convenient health care at half the typical price, today announced that it has begun offering...
Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication
16 oct. 2024 05h30 HE
|
Neurogastrx
Neurogastrx Announces Positive POC Data for Investigational Drug NG101 in Reducing Nausea & Vomiting Associated with GLP-1 Agonists